Narrative Update on Rossari Biotech
Analysts have maintained their fair value estimate for Rossari Biotech at ₹795.75, citing minimal changes in key financial assumptions and continued confidence in the company’s outlook.
What's in the News
- Successfully commissioned an additional 20,000 MTPA capacity at the Dahej facility during the quarter, bringing total installed capacity to 1,52,500 MTPA. (Key Developments)
- Commissioned 15,000 MTPA ethoxylation capacity at Unitop as part of a planned 30,000 MTPA expansion. Current installed capacity now stands at 51,000 MTPA. The second phase of this expansion is expected to be commissioned by the third quarter of fiscal year 2026. (Key Developments)
- The Board of Rossari Biotech has approved an investment of up to USD 8 million in tranches in Rossari International Limited Company, a wholly owned subsidiary in Saudi Arabia. The investment will support evaluation and expansion efforts to enhance the company's global presence. (Key Developments)
- The Board Meeting scheduled for October 15, 2025 will consider and approve unaudited financial results for the quarter and half year ended September 30, 2025. (Key Developments)
Valuation Changes
- Fair Value Estimate has been maintained at ₹795.75 with no change from the previous assessment.
- Discount Rate has risen slightly, moving from 13.59% to 13.63%.
- Revenue Growth expectation remains unchanged at approximately 15.30%.
- Net Profit Margin is stable, held at around 7.40%.
- Future P/E has increased marginally from 25.45x to 25.48x.
Have other thoughts on Rossari Biotech?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.